Drug intelligence / Profile preview

RJx-03 + RJx-07

Development stage: Preclinical
Lead developer: Rejuvenate Biomed
Administration: Oral

Overview

RJx-03 + RJx-07 is a combination drug candidate currently in the discovery or preclinical stage of development by Rejuvenate Biomed. The candidate was identified using the company's proprietary drug discovery ecosystem, which includes CombinAge, an AI-enabled in silico platform for identifying synergistic drug combinations, and CelegAge, an in vivo platform utilizing *C. elegans* to screen for effects on healthspan and lifespan. While the specific therapeutic targets and indications for RJx-03 + RJx-07 remain undisclosed, the program aligns with Rejuvenate Biomed's mission to develop therapies that target the underlying mechanisms of aging to treat age-related diseases.

Other names: RJx-03/RJx-07

Beyond the preview

Go deeper on RJx-03 + RJx-07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJx-03 + RJx-07.

Explore the full profile